Understanding how colon cancer develops at the genetic level can feel complicated, especially when terms like mismatch repair genes (MMR) and microsatellite instability (MSI-high) appear in a pathology report. These findings provide critical insight into how a tumor behaves, its potential responsiveness to treatment, and whether it may be linked to inherited cancer risk.
At Honest Pathology, we help patients interpret these results, explaining what they mean for colon cancer monitoring, prognosis, and follow-up.
What Are Mismatch Repair Genes?
Mismatch repair genes are part of the body’s natural DNA repair system. Their role is to correct errors that occur when cells divide and replicate DNA. When these genes—commonly MLH1, MSH2, MSH6, and PMS2—do not function properly, DNA errors accumulate. This can lead to abnormal cell growth and eventually contribute to cancer development, particularly in the colon.
When pathologists refer to “mismatch repair deficiency” in a colon cancer report, it means the tumor cells have lost the ability to correct DNA replication errors effectively.
How Colon Cancer Is Tested for Mismatch Repair Deficiency
Pathologists use tissue from a colon cancer biopsy or surgical specimen to test for mismatch repair deficiency. There are two main methods: immunohistochemistry (IHC) and molecular testing for microsatellite instability (MSI).
Immunohistochemistry involves staining the tumor tissue to see whether the key MMR proteins—MLH1, MSH2, MSH6, and PMS2—are present. Absence of one or more proteins suggests that the corresponding gene is not functioning. Molecular testing for MSI examines DNA sequences called microsatellites. Tumors that have a high rate of errors in these sequences are classified as MSI-high, indicating mismatch repair deficiency.
Both tests provide overlapping information, and sometimes both are performed to ensure accurate results.
What MSI-High Means in Colon Cancer
When a tumor is classified as MSI-high, it means the cancer cells have accumulated a significant number of DNA replication errors. MSI-high tumors behave differently from other colon cancers. Studies show that patients with MSI-high colon cancer often have a better prognosis in early-stage disease and may respond differently to certain chemotherapy and immunotherapy treatments.
MSI-high status also raises the possibility of Lynch syndrome, an inherited condition caused by germline mutations in mismatch repair genes. Identifying this can have implications for family members, who may benefit from genetic counseling and cancer screening.
Why Testing for Mismatch Repair Genes Is Important
Testing for MMR deficiency and MSI status serves multiple purposes. First, it can help predict prognosis, as tumors with MSI-high status may grow more slowly and have a lower chance of spreading in early stages. Second, it guides treatment decisions, since MSI-high tumors are more likely to respond to immunotherapy agents such as checkpoint inhibitors.
Third, MMR testing can help identify patients who may have hereditary cancer syndromes, such as Lynch syndrome. Knowing this information allows clinicians to recommend appropriate surveillance and preventive strategies for patients and their relatives.
How Pathology Reports Describe MMR and MSI
Pathology reports may use terms like “MMR-deficient,” “MMR-proficient,” “MSI-high,” “MSI-low,” or “microsatellite stable (MSS)”. MMR-proficient or microsatellite stable tumors have normal DNA repair function, whereas MMR-deficient or MSI-high tumors have lost this ability.
Patients may also see specific gene names listed in the report, indicating which protein was not detected in the immunohistochemistry study. For example, a report stating “loss of MLH1 and PMS2 expression” suggests that the MLH1 gene is not functioning, which is a pattern often associated with MSI-high tumors.
Who Should Consider MMR and MSI Testing
MMR and MSI testing is recommended for all newly diagnosed colon cancers, regardless of patient age, according to current guidelines. Testing is particularly important for patients with early-onset colon cancer, a family history of colorectal or related cancers, or multiple primary tumors, as it may indicate Lynch syndrome.
Even in older patients without a strong family history, MSI testing can provide prognostic information and guide treatment decisions.
Common Questions About MMR and MSI
Many patients want to know whether a finding of MSI-high means their cancer is hereditary. While MSI-high status raises suspicion, not all MSI-high tumors are due to inherited mutations. Some arise sporadically, particularly in tumors with MLH1 promoter hypermethylation. Genetic counseling and germline testing are necessary to determine whether Lynch syndrome is present.
Patients may also wonder how MSI status affects treatment. MSI-high colon cancers may be less responsive to certain chemotherapy regimens but show higher responsiveness to immunotherapy. Knowing the MSI status allows oncologists to tailor treatment plans more effectively.
Another common concern is prognosis. Studies consistently show that early-stage MSI-high colon cancers have a favorable prognosis, with lower rates of recurrence compared to microsatellite-stable cancers. However, advanced-stage MSI-high cancers may behave differently, highlighting the importance of individualized assessment.
Moving Forward With MMR and MSI Results
A report showing mismatch repair deficiency or MSI-high status provides valuable information for both the patient and the care team. It helps guide decisions about surveillance, treatment, and family risk assessment. Patients with these findings are encouraged to discuss genetic counseling, preventive strategies, and personalized treatment options with their healthcare providers.
At Honest Pathology, we help patients understand the meaning of MMR and MSI findings in their pathology reports. By explaining the implications for cancer behavior, treatment options, and family risk, we empower patients to make informed decisions about their health.
